"Francois Moisson, CEO at Excelya: “Our newly European scale and reach will allow us to provide a full suite of end-to-end clinical solutions for our clients where they need them."

Boulogne-Billancourt, France – July 6, 2020 –

Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services.

Thanks to the unification with these three companies, Excelya Group is now a leading European full service CRO providing services in 24 European countries. Excelya Group now employs 800 people in six areas of expertise, with expected combined revenues of €70 million in 2020.

About The Clinical Company

Founded in 2002, The Clinical Company is based in Amstelveen, The Netherlands and Leuven, near Brussels, Belgium. The Clinical Company specializes in delivering clinical services in the Benelux to their (Bio)Pharmaceutical, Medical Device and CRO Clients. The Clinical Company is a full service CRO that provides services from Phases I to IV in all major therapeutic areas and conducts clinical trials in eight countries in Western Europe.
For more information, please visit www.theclinicalcompany.com.

About Excelya Group

Excelya is now an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent
experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit www.excelya.com.

Legal and financial advisors:

• Excelya:
  
  • Legal counsel: FieldFisher: Philippe Netto, Hélène Lefebvre, Antoine Gabizon (Fr), Mark Walker (UK), Louis Bouchez and Jan Schouten (NL), Florian Streiber (D), Louis-Francois du Castillon (Bel) ;
    De Pardieu Brocas Maffei: Philippe Rozec
  • Financial Audit: Oderis, Aurélien Vion
  • Financing: Banking pool (SG,LCL, CIC, HSBC), leading agent: Société Générale, Erkan Suer

• Zeincro: CMS Cameron McKenna Nabarro Olswang LLP, John Finnemore
• The Clinical Company: CMS Derks Star Busmann N.V, Pieter van Duijvenvoorde, & Breezeholme Advisory Services, Pim van de Riet
• Koehler eClinical: Dr. Reinhard Hermes, & VALNES Corporate Finance GmbH, Michael Graser